![Matthew Ronsheim](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Matthew Ronsheim
Corporate Officer/Principal bij ENTASIS THERAPEUTICS HOLDINGS INC.
Vermogen: 639 653 $ op 31-05-2024
Actieve functies van Matthew Ronsheim
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ENTASIS THERAPEUTICS HOLDINGS INC. | Corporate Officer/Principal | 01-09-2020 | - |
Loopbaan van Matthew Ronsheim
Eerdere bekende functies van Matthew Ronsheim
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ENANTA PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 01-06-2016 | 01-08-2019 |
Corporate Officer/Principal | 01-06-2016 | 01-08-2019 |
Opleiding van Matthew Ronsheim
Southern Connecticut State University | Undergraduate Degree |
University of New Hampshire | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 5 |
Operationeel
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sectoraal
Health Technology | 3 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ENANTA PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Entasis Therapeutics Holdings, Inc.
![]() Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Beurs
- Insiders
- Matthew Ronsheim
- Ervaring